Library

This is a listing of publications relevant to this website.  Principally, these pertain to the DiSC/TRAC/SignatuRx personalized cytometric profiling assay and its use in the setting of CLL and other hematologic neoplasms.  A listing of all publications in the field of personalized cytometric profiling authored by Dr. Weisenthal may be found by following this link. A listing of personalized cytometric profiling publications authored by Dr. Bosanquet may be found by following this link.  There will be some overlap owing to collaborations between the two investigators which have occurred at intervals over a period of more than 30 years.

DiSC Assay Bibliography

  1. 1.Weisenthal LM, Marsden JA, Dill PL, et al. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983; 43:749–757.  Link to publication

  2. 2.Bosanquet AG, Bird MC, Price WJP, Gilby ED.  An assessment of a short-term tumour chemosensitivity assay in chronic lymphocytic leukaemia.  Br J Cancer 1983; 47: 781-789.

  3. 3.Weisenthal LM, Shoemaker RH, Marsden JA, et al. In vitro chemosensitivity assay based on the concept of total tumor cell kill. Recent Results Cancer Res 1984; 94:161–173. Link to publication

  4. 4.Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985; 69:615–632.  Link to publication

  5. 5.Bird MC, Bosanquet AG, Gilby ED.  In vitro determination of tumour chemosensitivity in haematological malignancies. Hematol Oncol 1985; 3: 1-10.

  6. 6.Bosanquet AG.  Stability of melphalan solutions during preparation and storage.  J Pharm Sci 1985; 74: 348-351.

  7. 7.Bosanquet AG.  Storage of chemotherapy drugs.  Int J Cell Cloning 1985; 3: 343-345. (Letter)

  8. 8.Bosanquet AG.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays.  General considerations, the nitrosoureas and alkylating agents.  Cancer Chemother Pharmacol 1985; 14: 83-95.

  9. 9.Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep. 1986 Nov;70(11):1283-95. [Seminal paper) Link to publication

  10. 10.Bosanquet AG.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays.  II. Assay methods, adriamycin and the other antitumour antibiotics.  Cancer Chemother Pharmacol 1986; 17: 1-10.

  11. 11.Bird MC, Bosanquet AG, Forskitt S, Gilby ED.  Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in vitro chemosensitivity of haematological malignancies.  Leuk Res 1986; 10: 445-449.

  12. 12.Bird MC, Forskitt S, Gilby ED, Bosanquet AG.  The influence of sample source and cell concentration on the in vitro chemosensitivity of haematological tumours.  Br J Cancer 1986; 53: 539-545.

  13. 13.Bosanquet AG, Clarke HE.  Chlorambucil: stability of solutions during preparation and storage.  Cancer Chemother Pharmacol 1986; 18: 176-179.

  14. 14.Bird MC, Godwin VAJ, Antrobus JH, Bosanquet AG.   Comparison of in vitro drug sensitivity by the differential staining cytotoxicity (DiSC) and colony-forming assays.  Br J Cancer 1987; 55: 429-431.

  15. 15.Bird MC, Bosanquet AG, Forskitt S, Gilby ED.  Long term comparison of results of a drug sensitivity assay in vitro with patient response in lymphatic neoplasms.  Cancer 1988; 61: 1104-1109.

  16. 16.Bosanquet AG, Bird MC.  Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays.  Cancer Chemother Pharmacol 1988; 21: 211-215.

  17. 17.Bosanquet AG.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays.  III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumour agents.  Cancer Chemother Pharmacol 1989; 23: 197-207.

  18. 18.Bosanquet AG, Forskitt S.  Effect of cell isolation methods and drug concentration on the use of the Differential Staining Cytotoxicity (DiSC) assay with solid tumours.  Cytotechnology 1989; 2: 225-232.

  19. 19.Weisenthal LM, Nagourney RA, Kern DH, Boullier B, Bosanquet AG, Dill PL, Messenger JC, Moran EM.  Approach to the clinical circumvention of drug resistance utilizing a non-clonogenic in vitro assay measuring the effects of drugs, radiation, and interleukin II on largely non-dividing cells.  Advan Clin Oncol 1989; 1: 91-111.

  20. 20.Bosanquet AG.  Correlations between therapeutic response of leukaemias and an in-vitro drug-sensitivity assay.  Lancet 1991; 337: 711-714.

  21. 21.Betteridge RF, Bosanquet AG.  Automated stability determination of anticancer drugs incubated in cell culture medium.  Int J Phamaceut 1991; 71: 73-79.

  22. 22.Weisenthal LM, Kern, DH. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays. Oncology (U.S.A.) 1992; 5:93–103 Individualized Tumor Response Testing in Leukemia and Lymphoma.  Link to Publication

  23. 23.Hinkley HJ, Bosanquet AG.  The in vitro radiosensitivity of lymphocytes from chronic lymphocytic leukaemia using the differential staining cytotoxicity (DiSC) assay.  I--Investigation of the method.  Int J Radiat Biol 1992; 61: 103-110.

  24. 24.Hinkley HJ, Bosanquet AG.  The in vitro radiosensitivity of lymphocytes from chronic lymphocytic leukaemia using the differential staining cytotoxicity (DiSC) assay.  II--Results on 40 patients.  Int J Radiat Biol 1992; 61: 111-121.

  25. 25.Weisenthal LM. Antineoplastic drug screening belongs in the laboratory, not in the clinic (editorial). J Natl Cancer Inst 1992; 84:466–469. Link to publication

  26. 26.Parker AN, Hutchinson RM, Chapman CS, Bosanquet AG.  Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.  Br J Haematol 1992; 81: 455-456.

  27. 27.Weisenthal LM. Cell culture assays for hematologic neoplasms based on the concept of total tumor cell kill. In: Kaspers GJL, Pieters R, Twentyman PR, et al., eds. Drug Resistance in Leukemia and Lymphoma: The Clinical Value of Laboratory Studies. Chur, Switzerland: Harwood Academic Publishers, 1993:415–432.

  28. 28.Fruehauf JP, Bosanquet AG.  In vitro determination of drug response: A discussion of clinical applications.  In: Cancer, Principals and Practice of Oncology, PPO updates.  Eds. DeVita VT, Hellman S, Rosenberg SA.  Philadelphia: Lippincott 1993; 7(12): 1-16.

  29. 29.Bosanquet AG, Bell PB.  Handling requirements to achieve active drugs in in vitro drug sensitivity and resistance assays.  In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (Eds.) "Drug resistance in leukemia and lymphoma.  The clinical value of laboratory studies."  London: Harwood 1993; 227-255.

  30. 30.Taylor AR, Bosanquet AG.  Use of S9 Liver microsomes in the DiSC assay to identify drugs requiring activation in vitro.  In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (Eds.) "Drug resistance in leukemia and lymphoma.  The clinical value of laboratory studies."  London: Harwood 1993; 257-262.

  31. 31.Bosanquet AG.  In vitro drug sensitivity testing for the individual patient - an ideal adjunct to current methods of treatment choice.  Clin Oncol 1993; 5: 195-197. Bosanquet AG.  The DiSC assay 10 years and 2000 tests further on.  In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (Eds.) "Drug resistance in leukemia and lymphoma.  The clinical value of laboratory studies."  London: Harwood 1993; 373-384.

  32. 32.Bosanquet AG.  Stability of solutions of anticancer drugs.  In: Florence AT, Salole E (Eds) "Topics in Pharmacy, Vol 3, Pharmaceutical aspects of cancer chemotherapy."  Oxford: Butterworth-Heinemann 1993; 82-103.

  33. 33.Hinkley HJ, Bosanquet AG.  The cross resistance between radiosensitivity and chemosensitivity of fresh human chronic lymphocytic leukaemic lymphocytes using the DiSC assay.  In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (Eds) "Drug resistance in leukemia and lymphoma.  The clinical value of laboratory studies."  London: Harwood 1993; 385-391.Bosanquet AG, Burlton AR.  Airborne cytotoxicity in the DiSC assay caused by solutions of treosulfan but not busulphan.  Cytotechnology 1994; 16: 131-136.

  34. 34.Bosanquet AG.  Short-term in vitro drug sensitivity tests for cancer chemotherapy.  A summary of correlations of test result with both patient response and survival.  Forum Trends Exp Clin Med 1994; 4: 179-195.

  35. 35.Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D.  Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.  Acta Haematol 1995; 93: 73-79.

  36. 36.Bosanquet AG.  The role of chemosensitivity testing in haematological malignancies.  Therapy Express 1995 (March); No. 98: 1-6.

  37. 37.Bosanquet AG, Bell PB.  Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology.  Leuk Res 1996; 20: 143-153.

  38. 38.Bosanquet AG, Bell PB.  Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukaemia.  Blood 1996; 87: 1962-1971.

  39. 39.Bosanquet AG, Bell PB, Burlton AR, Amos AS. Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival. Leuk Lymph 1996; 24: 141-147.

  40. 40.Bosanquet AG, Burlton AR, Bell PB, Harris AL.  Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP.  Br J Cancer 1997; 76: 511-518.

  41. 41.Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. The DiSC assay: a cost-effective guide to treatment for chronic lymphocytic leukaemia?  Int J Tech Assess Health Care 1999; 15: 173-184.

  42. 42.Bosanquet AG, Johnson SA, Richards SM.  Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.  Br J Haematol 1999; 106: 71-77.

  43. 43.Bosanquet AG, Copplestone JA, Johnson SAN, Smith AG, Povey SJ, Gillingham R, Oscier DG. Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay.  Br J Haematol 1999; 106: 474-476.

  44. 44.Bosanquet AG, Bell PB, Rooney N.  Effect of interleukin-2 on CD95 (Fas/APO-1) expression in fresh chronic lymphocytic leukaemia and mantle cell lymphoma cells: relationship to ex vivo chemoresponse.  Anticancer Res 1999; 19: 5329-5334.

  45. 45.Bosanquet AG, Bosanquet MI.  Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia.  Leukemia 2000; 14: 712-715.

  46. 46.Weisenthal LM, Nygren P. Current status of cell culture drug resistance testing (CCDRT). Human Tumor Assay Journal 2002. Link to publication

  47. 47.Bosanquet AG, Burlton AR, Bell PB.  Parameters affecting the ex vivo cytotoxic drug sensitivity of normal human cells.  J Exp Ther Oncol 2002; 2: 53-63.

  48. 48.Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B, Daniel PT. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.  Leukemia 2002; 16: 1035-1044.

  49. 49.Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT.  Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.  Cell Death Differ 2003; 10: 477-484.

  50. 50.Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, Joshi R, Mackie PH, Douglas IDC, Bowcock SJ, Catovsky D. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003 Dec; 82: 759-65.

  51. 51.Bosanquet AG, Bell PB.  Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumour cells. J Exp Ther Oncol 2004; 4: 145-154.

  52. 52.Sturm I, Bosanquet AG, Hummel M, Dörken B, Daniel PT.  In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease progression.  BioMed Central Cancer 2005; 5: 105.

  53. 53.Sturm I, Bosanquet AG, Radetzki S, Hummel M, Dörken B, Daniel PT.  Silencing of APAF-1 in B-CLL results in poor prognosis only in the case of concomitant p53 deletion.  Int J Cancer 2006; 118: 2329-2336.

  54. 54.Bosanquet AG.  Laboratory tests of cytotoxic drug sensitivity.  The Biomedical Scientist 2007; 51: 432-435.

  55. 55.Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P, on behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial.  Lancet 2007; 370: 230-239.

  56. 56.Bosanquet AG, Nygren P, and Weisenthal LM. Individualized Tumor Response Testing in Leukemia and Lymphoma; Innovative Leukemia and Lymphoma Therapy. May 2008 , 23 -43 Link to publication

  57. 57.Bosanquet AG, Richards SM, Wade R, Else M, Matutes E, Dyer MJS, Rassam SMB, Durant J, Scadding SM, Raper SL, Dearden CE, Catovsky D.  Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.  Br J Haem 2009; 146: 384-95.

  58. 58.Weisenthal LM. Methods Mol Biol. 2011;731:259-83. Differential Staining Cytotoxicity assay: a review. Link to publication

  59. 59.Melarangi T, Zhuang J, Lin K, Rockliffe N, Bosanquet AG, Oates M, Slupsky JR, Pettitt AR.  Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.  Cell Death Dis 2012; 3: e372. 10pp.  http://www.nature.com/cddis/journal/v3/n8/full/cddis2012102a.html.  Open access

  60. 60.Matutes E, Bosanquet AG, Wade R, Richards SM, Else M, Catovsky D. The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.  Leukemia. 2013; 27: 507-510. http://www.nature.com/leu/journal/v27/n2/full/leu2012209a.html.  Open access

  61. 61.Bennett TA, … Bosanquet AG, (+ 39 other authors). Pharmacological Profiles of Acute Myeloid Leukemia treatments in patient samples by automated flow cytometry; a bridge to individualized medicine.  Submitted